|
DE3587505T2
(de)
|
1984-10-04 |
1994-01-05 |
Sandoz Ag |
Monoklonale antikörper gegen zyklosporine.
|
|
EP0194972B1
(en)
|
1985-03-11 |
1992-07-29 |
Sandoz Ag |
Novel cyclosporins
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
|
EP0620230A1
(en)
|
1989-04-15 |
1994-10-19 |
Nippon Chemiphar Co., Ltd. |
Peptides and antidementia agents containing the same
|
|
PT98990A
(pt)
|
1990-09-19 |
1992-08-31 |
American Home Prod |
Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
|
|
US5120842A
(en)
|
1991-04-01 |
1992-06-09 |
American Home Products Corporation |
Silyl ethers of rapamycin
|
|
US5100883A
(en)
|
1991-04-08 |
1992-03-31 |
American Home Products Corporation |
Fluorinated esters of rapamycin
|
|
US5118678A
(en)
|
1991-04-17 |
1992-06-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
|
SG64322A1
(en)
|
1991-05-10 |
1999-04-27 |
Rhone Poulenc Rorer Int |
Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
|
|
US5118677A
(en)
|
1991-05-20 |
1992-06-02 |
American Home Products Corporation |
Amide esters of rapamycin
|
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
|
US5151413A
(en)
|
1991-11-06 |
1992-09-29 |
American Home Products Corporation |
Rapamycin acetals as immunosuppressant and antifungal agents
|
|
GB9125660D0
(en)
|
1991-12-03 |
1992-01-29 |
Smithkline Beecham Plc |
Novel compound
|
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
DE69302945T2
(de)
|
1992-03-27 |
1996-10-10 |
American Home Prod |
29-Demethoxyrapamycin zur Induktion der Immunosuppression
|
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
|
ZA935112B
(en)
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
|
ZA935111B
(en)
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
|
US5256790A
(en)
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
|
US5258389A
(en)
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
|
CA2148484A1
(en)
|
1992-11-13 |
1994-05-26 |
Stewart Lyman |
Novel cytokine designated elk ligand
|
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
|
GB9303681D0
(en)
|
1993-02-24 |
1993-04-14 |
Pitman Moore Inc |
Vaccines
|
|
US5516658A
(en)
|
1993-08-20 |
1996-05-14 |
Immunex Corporation |
DNA encoding cytokines that bind the cell surface receptor hek
|
|
ES2164713T3
(es)
|
1993-09-20 |
2002-03-01 |
Univ Leland Stanford Junior |
Produccion recombinante de nuevos poliquetidos.
|
|
CA2148931A1
(en)
|
1993-10-01 |
1995-04-13 |
Jurg Zimmermann |
Pyrimidineamine derivatives and processes for the preparation thereof
|
|
US5656643A
(en)
|
1993-11-08 |
1997-08-12 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
|
EP0729471A1
(en)
|
1993-11-19 |
1996-09-04 |
Abbott Laboratories |
Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
|
|
PL314238A1
(en)
|
1993-12-17 |
1996-09-02 |
Sandoz Ltd |
Rapamycin derivatives
|
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
|
WO1995024190A2
(en)
|
1994-03-07 |
1995-09-14 |
Sugen, Inc. |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
|
IL112873A
(en)
|
1994-03-08 |
2005-03-20 |
Wyeth Corp |
Rapamycin-fkbp12 binding proteins, their isolation and their use
|
|
EP0756627A1
(en)
|
1994-04-15 |
1997-02-05 |
Amgen Inc. |
Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
|
|
DK0682027T3
(da)
|
1994-05-03 |
1998-05-04 |
Ciba Geigy Ag |
Pyrrolopyrimidinderivater med antiproliferativ virkning
|
|
GB9410142D0
(en)
|
1994-05-20 |
1994-07-06 |
Univ Warwick |
Carbapenems
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US6303769B1
(en)
|
1994-07-08 |
2001-10-16 |
Immunex Corporation |
Lerk-5 dna
|
|
US5919905A
(en)
|
1994-10-05 |
1999-07-06 |
Immunex Corporation |
Cytokine designated LERK-6
|
|
GB9524630D0
(en)
|
1994-12-24 |
1996-01-31 |
Zeneca Ltd |
Chemical compounds
|
|
US6057124A
(en)
|
1995-01-27 |
2000-05-02 |
Amgen Inc. |
Nucleic acids encoding ligands for HEK4 receptors
|
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
EP2163546B1
(en)
|
1995-03-30 |
2016-06-01 |
Pfizer Products Inc. |
Quinazoline derivatives
|
|
DE69609602T2
(de)
|
1995-04-03 |
2001-04-12 |
Novartis Ag, Basel |
Pyrazolderivate und verfahren zu deren herstellung
|
|
US5861510A
(en)
|
1995-04-20 |
1999-01-19 |
Pfizer Inc |
Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
|
CA2219659C
(en)
|
1995-06-09 |
2008-03-18 |
Novartis Ag |
Rapamycin derivatives
|
|
US5624677A
(en)
|
1995-06-13 |
1997-04-29 |
Pentech Pharmaceuticals, Inc. |
Controlled release of drugs delivered by sublingual or buccal administration
|
|
US6124453A
(en)
|
1995-07-04 |
2000-09-26 |
Novartis Ag |
Macrolides
|
|
TR199800012T1
(xx)
|
1995-07-06 |
1998-04-21 |
Novartis Ag |
Piroloprimidinler ve preparasyon i�in tatbikler.
|
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
DE69624081T2
(de)
|
1995-12-20 |
2003-06-12 |
Agouron Pharmaceuticals, Inc. |
Matrix-metalloprotease Inhibitoren
|
|
JP4275733B2
(ja)
|
1996-01-23 |
2009-06-10 |
ノバルティス アクチエンゲゼルシャフト |
ピロロピリミジンおよびその製造法
|
|
JP3406763B2
(ja)
|
1996-01-30 |
2003-05-12 |
東レ・ダウコーニング・シリコーン株式会社 |
シリコーンゴム組成物
|
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9603097D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
|
DE19608588A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
DE19629652A1
(de)
|
1996-03-06 |
1998-01-29 |
Thomae Gmbh Dr K |
4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
WO1997034895A1
(de)
|
1996-03-15 |
1997-09-25 |
Novartis Ag |
NEUE N-7 HETEROCYCLYL-PYRROLO[2,3-d]PYRIMIDINE UND IHRE VERWENDUNG
|
|
DE69710712T3
(de)
|
1996-04-12 |
2010-12-23 |
Warner-Lambert Co. Llc |
Umkehrbare inhibitoren von tyrosin kinasen
|
|
GB9607729D0
(en)
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
|
CA2258548C
(en)
|
1996-06-24 |
2005-07-26 |
Pfizer Inc. |
Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
|
|
WO1998001571A2
(en)
|
1996-07-05 |
1998-01-15 |
Biotica Technology Limited |
Erythromycins and process for their preparation
|
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
|
EP0937082A2
(en)
|
1996-07-12 |
1999-08-25 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
|
EP0912559B1
(en)
|
1996-07-13 |
2002-11-06 |
Glaxo Group Limited |
Fused heterocyclic compounds as protein tyrosine kinase inhibitors
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
ES2191187T3
(es)
|
1996-07-13 |
2003-09-01 |
Glaxo Group Ltd |
Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
|
|
EA199900036A1
(ru)
|
1996-07-18 |
1999-06-24 |
Пфайзер Инк |
Ингибиторы металлопротеаз матрикса на основе фосфинатов, фармацевтическая композиция, способ лечения
|
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
AU4055697A
(en)
|
1996-08-16 |
1998-03-06 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
ATE384062T1
(de)
|
1996-08-23 |
2008-02-15 |
Novartis Pharma Gmbh |
Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
|
|
PL331895A1
(en)
|
1996-08-23 |
1999-08-16 |
Pfizer |
Arylosulphonylamino derivatives of hydroxamic acid
|
|
SE9603465D0
(sv)
|
1996-09-23 |
1996-09-23 |
Astra Ab |
New compounds
|
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
|
WO1998014449A1
(en)
|
1996-10-02 |
1998-04-09 |
Novartis Ag |
Fused pyrazole derivatives and processes for their preparation
|
|
EP0929553B1
(en)
|
1996-10-02 |
2005-03-16 |
Novartis AG |
Pyrimidine derivatives and processes for the preparation thereof
|
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
|
GB9621757D0
(en)
|
1996-10-18 |
1996-12-11 |
Ciba Geigy Ag |
Phenyl-substituted bicyclic heterocyclyl derivatives and their use
|
|
DK0950059T3
(da)
|
1997-01-06 |
2004-11-01 |
Pfizer |
Cycliske sulfonderivater
|
|
ATE248812T1
(de)
|
1997-02-03 |
2003-09-15 |
Pfizer Prod Inc |
Arylsulfonylhydroxamsäurederivate
|
|
KR20000070751A
(ko)
|
1997-02-05 |
2000-11-25 |
로즈 암스트롱, 크리스틴 에이. 트러트웨인 |
세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
|
|
JP2000507975A
(ja)
|
1997-02-07 |
2000-06-27 |
ファイザー・インク |
Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
|
|
PL334997A1
(en)
|
1997-02-11 |
2000-03-27 |
Pfizer |
Derivatives or arylosulphonyl-hydroxamic acid
|
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
|
US6902913B2
(en)
|
1997-04-30 |
2005-06-07 |
Kosan Biosciences, Inc. |
Recombinant narbonolide polyketide synthase
|
|
US6150395A
(en)
|
1997-05-30 |
2000-11-21 |
The Regents Of The University Of California |
Indole-3-carbinol (I3C) derivatives and methods
|
|
WO1999007701A1
(en)
|
1997-08-05 |
1999-02-18 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
|
BR9811868A
(pt)
|
1997-08-08 |
2000-08-15 |
Pfizer Prod Inc |
Derivados de ácido ariloxiarilsulfonilamino hidroxâmico
|
|
AU1102399A
(en)
|
1997-10-21 |
1999-05-10 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
|
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
|
US6153383A
(en)
|
1997-12-09 |
2000-11-28 |
Verdine; Gregory L. |
Synthetic transcriptional modulators and uses thereof
|
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
|
IL137409A0
(en)
|
1998-02-09 |
2001-07-24 |
Genentech Inc |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
|
AU756838B2
(en)
|
1998-03-04 |
2003-01-23 |
Bristol-Myers Squibb Company |
Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
|
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
|
WO1999061055A1
(en)
|
1998-05-22 |
1999-12-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Bifunctional molecules and therapies based thereon
|
|
HUP0103617A2
(hu)
|
1998-05-29 |
2002-02-28 |
Sugen, Inc. |
Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
|
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
|
EP1097147A4
(en)
|
1998-07-10 |
2001-11-21 |
Merck & Co Inc |
NEW ANGIOGENESIS INHIBITORS
|
|
AU760020B2
(en)
|
1998-08-31 |
2003-05-08 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
|
ATE346938T1
(de)
|
1998-10-02 |
2006-12-15 |
Kosan Biosciences Inc |
Polyketid synthase enzyme und rekombinante dna konstrukte dafür, zur herstellung von mit fk-506 und fk-520 verwandten verbindungen
|
|
US6686454B1
(en)
|
1998-10-09 |
2004-02-03 |
Isotechnika, Inc. |
Antibodies to specific regions of cyclosporine related compounds
|
|
ES2213985T3
(es)
|
1998-11-05 |
2004-09-01 |
Pfizer Products Inc. |
Derivados de hidroxiamida de acido 5-oxo-pirrolidin-2-carboxilico.
|
|
AU2876300A
(en)
|
1999-02-09 |
2000-08-29 |
Board Of Trustees Of The Leland Stanford Junior University |
Methods to mediate polyketide synthase module effectiveness
|
|
DE60028740T2
(de)
|
1999-03-30 |
2007-05-24 |
Novartis Ag |
Phthalazinderivate zur behandlung von entzündlichen erkrankungen
|
|
GB9912961D0
(en)
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
|
ATE324444T1
(de)
|
1999-06-07 |
2006-05-15 |
Immunex Corp |
Tek-antagonisten
|
|
US6521424B2
(en)
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
|
WO2001003720A2
(en)
|
1999-07-12 |
2001-01-18 |
Genentech, Inc. |
Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
|
|
CA2383451A1
(en)
|
1999-08-24 |
2001-03-01 |
Ariad Gene Therapeutics, Inc. |
28-epirapalogs
|
|
EP1676845B1
(en)
|
1999-11-05 |
2008-06-11 |
AstraZeneca AB |
New quinazoline derivatives
|
|
GB9927191D0
(en)
|
1999-11-17 |
2000-01-12 |
Angeletti P Ist Richerche Bio |
Methods and means for regulation of gene expression
|
|
EP1230353A4
(en)
|
1999-11-19 |
2002-11-06 |
Univ Leland Stanford Junior |
BIFUNCTIONAL MOLECULES AND THEIR USE IN THE DESTRUCTION OF PROTEIN-PROTEIN INTERACTIONS
|
|
US7220552B1
(en)
|
1999-11-19 |
2007-05-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Bifunctional molecules and their use in the disruption of protein-protein interactions
|
|
EP1233943B1
(en)
|
1999-11-24 |
2011-06-29 |
Sugen, Inc. |
Ionizable indolinone derivatives and their use as ptk ligands
|
|
US6515004B1
(en)
|
1999-12-15 |
2003-02-04 |
Bristol-Myers Squibb Company |
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
|
|
US6727225B2
(en)
|
1999-12-20 |
2004-04-27 |
Immunex Corporation |
TWEAK receptor
|
|
AU784995B2
(en)
|
2000-02-08 |
2006-08-17 |
Sinvent As |
Novel genes encoding a nystatin polyketide synthase and their manipulation and utility
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
ES2302726T3
(es)
|
2000-02-24 |
2008-08-01 |
Invitrogen Corporation |
Estimulacion y concentracion simultanea de celulas.
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7074408B2
(en)
|
2000-02-25 |
2006-07-11 |
Immunex Corporation |
Use of integrin antagonists to inhibit angiogenesis
|
|
KR20020025959A
(ko)
|
2000-05-23 |
2002-04-04 |
버텍스 파마슈티칼스 인코포레이티드 |
카스파제 억제제 및 이의 용도
|
|
US7176037B2
(en)
|
2000-07-13 |
2007-02-13 |
The Scripps Research Institute |
Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
|
|
US6630500B2
(en)
|
2000-08-25 |
2003-10-07 |
Cephalon, Inc. |
Selected fused pyrrolocarbazoles
|
|
CN1307173C
(zh)
|
2000-12-21 |
2007-03-28 |
葛兰素集团有限公司 |
作为血管生成调节剂的嘧啶胺
|
|
US20020147198A1
(en)
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
|
US7105682B2
(en)
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
WO2003014311A2
(en)
|
2001-08-06 |
2003-02-20 |
Kosan Biosciences, Inc. |
Methods for altering polyketide synthase genes
|
|
US6809077B2
(en)
|
2001-10-12 |
2004-10-26 |
Enanta Pharmaceuticals, Inc. |
Cyclosporin analogs for the treatment of autoimmune diseases
|
|
US6987090B2
(en)
|
2002-05-09 |
2006-01-17 |
Lg Household & Health Care Ltd. |
Use of 3-position cyclosporin derivatives for hair growth
|
|
US7307088B2
(en)
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
|
US7012065B2
(en)
|
2003-02-07 |
2006-03-14 |
Enanta Pharmaceuticals, Inc. |
Cyclosporins for the treatment of immune disorders
|
|
EP1477563A3
(en)
|
2003-05-16 |
2004-11-24 |
Wyeth |
Cloning genes from streptomyces cyaneogriseus subsp.noncyanogenus for biosynthesis of antibiotics and methods of use
|
|
KR20060052681A
(ko)
|
2003-05-23 |
2006-05-19 |
와이어쓰 |
Ｇｉｔｒ 리간드, ｇｉｔｒ 리간드-연관 분자, 항체 및그의 용도
|
|
PT1646634E
(pt)
|
2003-07-08 |
2009-02-16 |
Novartis Ag |
Utilização de rapamicina e derivados de rapamicina para o tratamento de perda óssea
|
|
WO2005016252A2
(en)
|
2003-07-11 |
2005-02-24 |
Ariad Gene Therapeutics, Inc. |
Phosphorus-containing macrocycles
|
|
WO2005007190A1
(en)
|
2003-07-11 |
2005-01-27 |
Schering Corporation |
Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
|
|
TW200523262A
(en)
|
2003-07-29 |
2005-07-16 |
Smithkline Beecham Corp |
Inhibitors of AKT activity
|
|
EP2287156B1
(en)
|
2003-08-15 |
2013-05-29 |
Novartis AG |
2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
|
|
WO2005055808A2
(en)
|
2003-12-02 |
2005-06-23 |
Genzyme Corporation |
Compositions and methods to diagnose and treat lung cancer
|
|
WO2005094314A2
(en)
|
2004-03-26 |
2005-10-13 |
The Burnham Institute |
Modulators of shp2 tyrosine phosphatase and their use in the treatment of body weight disorders
|
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
|
EP1765402A2
(en)
|
2004-06-04 |
2007-03-28 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
|
PL1786785T3
(pl)
|
2004-08-26 |
2010-08-31 |
Pfizer |
Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
|
|
MX2007004489A
(es)
|
2004-10-13 |
2007-09-21 |
Wyeth Corp |
Analogos de 17-hidroxiwortamina como inhibidores pi3k.
|
|
CA2602777C
(en)
|
2005-03-25 |
2018-12-11 |
Tolerrx, Inc. |
Gitr binding molecules and uses therefor
|
|
PL2161336T5
(pl)
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
CN101267824A
(zh)
|
2005-09-20 |
2008-09-17 |
辉瑞产品公司 |
使用酪氨酸激酶抑制剂的治疗剂型和方法
|
|
WO2007133822A1
(en)
|
2006-01-19 |
2007-11-22 |
Genzyme Corporation |
Gitr antibodies for the treatment of cancer
|
|
US8653238B2
(en)
|
2006-02-27 |
2014-02-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for transport of molecules with enhanced release properties across biological barriers
|
|
US20070203168A1
(en)
|
2006-02-28 |
2007-08-30 |
Zhao Jonathon Z |
Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same
|
|
WO2007117699A2
(en)
|
2006-04-07 |
2007-10-18 |
University Of South Florida |
Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-87877, nsc-117199 and their analogs
|
|
US7601852B2
(en)
|
2006-05-11 |
2009-10-13 |
Kosan Biosciences Incorporated |
Macrocyclic kinase inhibitors
|
|
AU2007329352B2
(en)
|
2006-12-07 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Phosphoinositide 3-kinase inhibitor compounds and methods of use
|
|
WO2008124815A1
(en)
|
2007-04-10 |
2008-10-16 |
University Of South Florida |
Method of activating nk cells
|
|
ES2591281T3
(es)
|
2007-07-12 |
2016-11-25 |
Gitr, Inc. |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
|
PE20090678A1
(es)
|
2007-09-12 |
2009-06-27 |
Genentech Inc |
Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso
|
|
WO2009049098A2
(en)
|
2007-10-09 |
2009-04-16 |
Indiana University Research & Technology Corporation |
Materials and methods for regulating the activity of phosphatases
|
|
KR100945483B1
(ko)
|
2007-10-25 |
2010-03-05 |
이화여자대학교 산학협력단 |
ｐｉｋＤ 조절유전자의 발현벡터를 이용한 스트렙토미세스베네주엘라에（Ｓｔｒｅｐｔｏｍｙｃｅｓｖｅｎｅｚｕｅｌａｅ）에서폴리케타이드（ｐｏｌｙｋｅｔｉｄｅ）의 생산성 증가방법
|
|
JP5348725B2
(ja)
|
2007-10-25 |
2013-11-20 |
ジェネンテック， インコーポレイテッド |
チエノピリミジン化合物の製造方法
|
|
GB0805363D0
(en)
|
2008-03-20 |
2008-04-30 |
Sinvent As |
Novel NRPS-PKS gene cluster and its manipulation and utility
|
|
WO2009135000A2
(en)
|
2008-04-30 |
2009-11-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-117199 and analogs
|
|
AU2009266873A1
(en)
|
2008-07-02 |
2010-01-07 |
Emergent Product Development Seattle, Llc |
TGF-beta antagonist multi-target binding proteins
|
|
WO2010011666A2
(en)
|
2008-07-21 |
2010-01-28 |
University Of South Florida |
Indoline scaffold shp-2 inhibitors and cancer treatment method
|
|
JPWO2010030002A1
(ja)
|
2008-09-12 |
2012-02-02 |
国立大学法人三重大学 |
外来性ｇｉｔｒリガンド発現細胞
|
|
EP2352526A1
(en)
|
2008-09-19 |
2011-08-10 |
Protox Therapeutics Inc. |
Treating cancer stem cells using targeted cargo proteins
|
|
WO2010034243A1
(en)
|
2008-09-24 |
2010-04-01 |
Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences |
Novel gene cluster
|
|
AU2010208071C1
(en)
|
2009-01-30 |
2013-06-20 |
Enanta Pharmaceuticals, Inc. |
Cyclosporin analogues for preventing or treating hepatitis C infection
|
|
US9211291B2
(en)
|
2009-04-06 |
2015-12-15 |
Wyeth Llc |
Treatment regimen utilizing neratinib for breast cancer
|
|
WO2010121212A2
(en)
|
2009-04-17 |
2010-10-21 |
H. Lee Moffit Cancer Center And Research Institute, Inc. |
Indoline scaffold shp-2 inhibitors and method of treating cancer
|
|
CA2768299C
(en)
|
2009-07-13 |
2018-03-20 |
President And Fellows Of Harvard College |
Bifunctional stapled polypeptides and uses thereof
|
|
US8664186B2
(en)
|
2009-07-24 |
2014-03-04 |
Universite De Lorraine |
Stambomycin and derivatives, their production and their uses as drugs
|
|
BR112012003637A2
(pt)
|
2009-08-17 |
2017-04-25 |
Memorial Sloan Kettering Cancer Center |
"compostos de ligação de proteína de choque térmico, composições, e métodos para preparar e usar os mesmos"
|
|
CA2772613C
(en)
|
2009-09-03 |
2020-03-10 |
Schering Corporation |
Anti-gitr antibodies
|
|
CN102712675A
(zh)
|
2009-09-22 |
2012-10-03 |
爱勒让治疗公司 |
拟肽大环化合物
|
|
EP2492344B1
(en)
|
2009-10-22 |
2016-04-06 |
PeptiDream Inc. |
Rapid display method in translational synthesis of peptide
|
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
|
HUE029257T2
(en)
|
2009-12-29 |
2017-02-28 |
Aptevo Res And Dev Llc |
Heterodimer binding proteins and their use
|
|
EP2533784B1
(en)
|
2010-02-09 |
2015-04-22 |
Neurovive Pharmaceutical AB |
Sanglifehrin based compounds
|
|
US8637684B2
(en)
|
2010-05-12 |
2014-01-28 |
Wisconsin Alumni Research Foundation |
Tautomycetin and tautomycetin analog biosynthesis
|
|
WO2012041524A1
(en)
|
2010-10-01 |
2012-04-05 |
Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) |
Hydrazonopyrazolones as protein tyrosine phosphatase inhibitors
|
|
WO2012075048A2
(en)
|
2010-11-30 |
2012-06-07 |
The Johns Hopkins University |
Hybrid cyclic libraries and screens thereof
|
|
AR084217A1
(es)
|
2010-12-10 |
2013-05-02 |
Gilead Sciences Inc |
Inhibidores macrociclicos de virus flaviviridae
|
|
US9428845B1
(en)
|
2010-12-28 |
2016-08-30 |
Warp Drive Bio, Inc. |
Identifying new therapeutic agents
|
|
MX2013010871A
(es)
|
2011-03-23 |
2014-01-31 |
Amgen Inc |
Inhibidores dobles triciclicos fusionados de cdk 4/6 y flt3.
|
|
JO3063B1
(ar)
|
2011-03-29 |
2017-03-15 |
Neurovive Pharmaceutical Ab |
مركب مبتكر وطرق لانتاجه
|
|
AU2012257513B2
(en)
|
2011-05-19 |
2017-05-11 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Macrocyclic compounds as protein kinase inhibitors
|
|
US9260484B2
(en)
|
2011-06-15 |
2016-02-16 |
Ohio State Innovation Foundation |
Small molecule composite surfaces as inhibitors of protein-protein interactions
|
|
WO2013001310A1
(en)
|
2011-06-30 |
2013-01-03 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
Macrocyclic compounds and their use as cdk8 inhibitors
|
|
TW201311689A
(zh)
|
2011-08-05 |
2013-03-16 |
必治妥美雅史谷比公司 |
作為因子ｘｉａ抑制劑之新穎巨環化合物
|
|
DE102011111991A1
(de)
|
2011-08-30 |
2013-02-28 |
Lead Discovery Center Gmbh |
Neue Cyclosporin-Derivate
|
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
|
EP2836482B1
(en)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
|
US9090653B2
(en)
*
|
2012-06-08 |
2015-07-28 |
Gilead Sciences, Inc. |
Macrocyclic inhibitors of flaviviridae viruses
|
|
AR091279A1
(es)
|
2012-06-08 |
2015-01-21 |
Gilead Sciences Inc |
Inhibidores macrociclicos de virus flaviviridae
|
|
SG11201408047XA
(en)
*
|
2012-06-08 |
2015-01-29 |
Gilead Sciences Inc |
Macrocyclic inhibitors of flaviviridae viruses
|
|
WO2014009774A1
(en)
|
2012-07-12 |
2014-01-16 |
Hangzhou Dac Biotech Co., Ltd |
Conjugates of cell binding molecules with cytotoxic agents
|
|
JP6133431B2
(ja)
|
2012-11-24 |
2017-05-24 |
ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． |
親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
|
|
WO2014113584A1
(en)
|
2013-01-16 |
2014-07-24 |
Rhode Island Hospital |
Compositions and methods for the prevention and treatment of osteolysis and osteoporosis
|
|
RS56269B1
(sr)
|
2013-02-07 |
2017-11-30 |
Merck Patent Gmbh |
Makrociklični piridazinon derivati
|
|
JP6333943B2
(ja)
|
2013-03-15 |
2018-05-30 |
ノバルティス アーゲー |
抗体薬物コンジュゲート
|
|
WO2014143659A1
(en)
|
2013-03-15 |
2014-09-18 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the gtpase k-ras g12c
|
|
AU2014239542A1
(en)
|
2013-03-15 |
2015-10-01 |
Araxes Pharma Llc |
Covalent inhibitors of KRas G12C
|
|
CA2909310A1
(en)
|
2013-04-12 |
2014-10-16 |
Asana Biosciences, Llc |
Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways
|
|
AU2014256984B2
(en)
|
2013-04-26 |
2019-02-14 |
Indiana University Research & Technology Corporation |
Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)
|
|
WO2014180271A1
(zh)
|
2013-05-10 |
2014-11-13 |
苏州明锐医药科技有限公司 |
阿法替尼及其中间体的制备方法
|
|
EP2806274A1
(en)
|
2013-05-24 |
2014-11-26 |
AIT Austrian Institute of Technology GmbH |
Lung cancer diagnostic method and means
|
|
EP3016652A4
(en)
|
2013-07-03 |
2017-03-08 |
Indiana University Research and Technology Corporation |
Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors
|
|
EP2826586A1
(en)
|
2013-07-18 |
2015-01-21 |
Siemens Aktiengesellschaft |
A method and a system for machining an object
|
|
KR20160076519A
(ko)
|
2013-10-10 |
2016-06-30 |
아락세스 파마 엘엘씨 |
Kras g12c 억제제
|
|
WO2015107493A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
|
|
ES2699354T3
(es)
|
2014-01-17 |
2019-02-08 |
Novartis Ag |
Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2
|
|
US10233431B2
(en)
|
2014-02-26 |
2019-03-19 |
The Regents Of The University Of California |
Producing 3-hydroxycarboxylic acid and ketone using polyketide synthases
|
|
US20170067894A1
(en)
|
2014-03-03 |
2017-03-09 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Method and device for detection of pseudomonas aeruginosa
|
|
RU2017104856A
(ru)
|
2014-07-16 |
2018-08-16 |
Новоджен Лтд |
Функционализированные и замещенные индолы в качестве противораковых средств
|
|
JO3474B1
(ar)
|
2014-08-29 |
2020-07-05 |
Amgen Inc |
مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
|
|
WO2016049524A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
|
US10533016B2
(en)
|
2015-01-09 |
2020-01-14 |
Revolution Medicines, Inc. |
Compounds that participate in cooperative binding and uses thereof
|
|
TW201629069A
(zh)
|
2015-01-09 |
2016-08-16 |
霍普驅動生物科技股份有限公司 |
參與協同結合之化合物及其用途
|
|
WO2016160362A1
(en)
|
2015-03-31 |
2016-10-06 |
Allergan, Inc. |
Cyclosporins modified on the mebmt sidechain by heterocyclic rings
|
|
BR112017021869A2
(pt)
|
2015-04-10 |
2018-12-11 |
Araxes Pharma Llc |
compostos quinazolina substituídos e métodos de uso dos mesmos
|
|
US10428064B2
(en)
|
2015-04-15 |
2019-10-01 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of KRAS and methods of use thereof
|
|
WO2016191328A1
(en)
|
2015-05-22 |
2016-12-01 |
Allosta Pharmaceuticals |
Methods to prepare and employ binding site models for modulation of phosphatase activity and selectivity determination
|
|
WO2016196591A1
(en)
|
2015-06-01 |
2016-12-08 |
Indiana University Research & Technology Corporation |
Protein tyrosine phosphatases or shp2 inhibitors and uses thereof
|
|
WO2016203404A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
|
WO2016203405A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
|
CN107922388B
(zh)
|
2015-06-19 |
2020-12-29 |
诺华股份有限公司 |
用于抑制shp2活性的化合物和组合物
|
|
CA2993013A1
(en)
|
2015-07-22 |
2017-01-26 |
Araxes Pharma Llc |
Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
|
|
EP3356339A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP4242304A3
(en)
|
2015-10-01 |
2024-02-07 |
Revolution Medicines, Inc. |
Methods and reagents for analyzing protein-protein interfaces
|
|
WO2017078499A2
(ko)
|
2015-11-06 |
2017-05-11 |
경북대학교 산학협력단 |
단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
|
|
US11008372B2
(en)
|
2015-11-07 |
2021-05-18 |
Board Of Regents, The University Of Texas System |
Targeting proteins for degradation
|
|
MX2018005967A
(es)
|
2015-11-16 |
2018-08-29 |
Araxes Pharma Llc |
Compuestos de quinazolina 2-sustituida que comprenden un grupo heterociclico sustituido y metodos de uso de los mismos.
|
|
CR20180323A
(es)
|
2015-11-20 |
2018-08-06 |
Idorsia Pharmaceuticals Ltd |
Derivados de indol n-sustituídos como moduladores de los receptores de pge2
|
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
US9932288B2
(en)
|
2015-12-09 |
2018-04-03 |
West Virginia University |
Chemical compound for inhibition of SHP2 function and for use as an anti-cancer agent
|
|
WO2017156397A1
(en)
|
2016-03-11 |
2017-09-14 |
Board Of Regents, The University Of Texas Sysytem |
Heterocyclic inhibitors of ptpn11
|
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
JP7039489B2
(ja)
|
2016-05-18 |
2022-03-22 |
ミラティ セラピューティクス， インコーポレイテッド |
Ｋｒａｓ ｇ１２ｃ阻害剤
|
|
AU2017274199B2
(en)
|
2016-05-31 |
2021-09-23 |
Board Of Regents, The University Of Texas System |
Heterocyclic inhibitors of PTPN11
|
|
JP6751203B2
(ja)
|
2016-06-07 |
2020-09-02 |
ジャコバイオ ファーマスーティカルズ カンパニー リミテッドＪａｃｏｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． |
Ｓｈｐ２阻害剤として有用な新規複素環式誘導体
|
|
TWI806832B
(zh)
|
2016-07-12 |
2023-07-01 |
美商銳新醫藥公司 |
作為異位shp2抑制劑之2,5-雙取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪
|
|
JP2019529484A
(ja)
|
2016-09-29 |
2019-10-17 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
JP2020501519A
(ja)
|
2016-10-28 |
2020-01-23 |
ギンゴー バイオワークス， インコーポレイテッド |
化合物の生産のための組成物および方法
|
|
WO2018091634A1
(en)
*
|
2016-11-18 |
2018-05-24 |
Neurovive Pharmaceutical Ab |
Use of sanglifehrin macrocyclic analogues as anticancer compounds
|
|
MX392368B
(es)
|
2016-12-15 |
2025-03-24 |
Univ California |
Composiciones y metodos para el tratamiento del cancer
|
|
EA201991528A1
(ru)
|
2016-12-22 |
2020-01-16 |
Эмджен Инк. |
БЕНЗИЗОТИАЗОЛЬНЫЕ, ИЗОТИАЗОЛО[3,4-b]ПИРИДИНОВЫЕ, ХИНАЗОЛИНОВЫЕ, ФТАЛАЗИНОВЫЕ, ПИРИДО[2,3-d]ПИРИДАЗИНОВЫЕ И ПИРИДО[2,3-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ G12C KRAS ДЛЯ ЛЕЧЕНИЯ РАКА ЛЕГКОГО, РАКА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ ИЛИ КОЛОРЕКТАЛЬНОГО РАКА
|
|
US10988766B2
(en)
|
2017-01-06 |
2021-04-27 |
Oregon Health & Science University |
Compositions and methods used in diagnosing and treating colorectal cancer
|
|
ES2964956T3
(es)
|
2017-01-10 |
2024-04-10 |
Novartis Ag |
Combinación farmacéutica que comprende un inhibidor de ALK y un inhibidor de SHP2
|
|
AU2018210770B2
(en)
|
2017-01-23 |
2022-03-24 |
Revolution Medicines, Inc. |
Bicyclic compounds as allosteric SHP2 inhibitors
|
|
BR112019014527A2
(pt)
|
2017-01-23 |
2020-02-27 |
Revolution Medicines, Inc. |
Compostos de piridina como inibidores de shp2 alostéricos
|
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
WO2018140598A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused n-heterocyclic compounds and methods of use thereof
|
|
EP3573970A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
|
WO2018140600A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
|
US11358959B2
(en)
|
2017-01-26 |
2022-06-14 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
JOP20190186A1
(ar)
|
2017-02-02 |
2019-08-01 |
Astellas Pharma Inc |
مركب كينازولين
|
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
SG11201908820VA
(en)
|
2017-03-23 |
2019-10-30 |
Jacobio Pharmaceuticals Co Ltd |
Novel heterocyclic derivatives useful as shp2 inhibitors
|
|
US20200199102A1
(en)
|
2017-04-05 |
2020-06-25 |
Revolution Medicines, Inc. |
Compounds that participate in cooperative binding and uses thereof
|
|
JP2020520988A
(ja)
|
2017-04-05 |
2020-07-16 |
レボリューション メディシンズ インコーポレイテッドＲｅｖｏｌｕｔｉｏｎ Ｍｅｄｉｃｉｎｅｓ，Ｉｎｃ． |
タンパク質−タンパク質界面を分析するための方法及び試薬
|
|
US10800787B2
(en)
|
2017-04-20 |
2020-10-13 |
Apotex Inc. |
Process for the preparation of acalabrutinib
|
|
JP7348071B2
(ja)
|
2017-05-02 |
2023-09-20 |
レヴォリューション・メディスンズ，インコーポレイテッド |
ｍＴＯＲ阻害剤としてのラパマイシン類似体
|
|
WO2018206539A1
(en)
|
2017-05-11 |
2018-11-15 |
Astrazeneca Ab |
Heteroaryl compounds that inhibit g12c mutant ras proteins
|
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
|
US10745385B2
(en)
|
2017-05-25 |
2020-08-18 |
Araxes Pharma Llc |
Covalent inhibitors of KRAS
|
|
CN110831933A
(zh)
|
2017-05-25 |
2020-02-21 |
亚瑞克西斯制药公司 |
喹唑啉衍生物作为突变kras、hras或nras的调节剂
|
|
SG11202001282UA
(en)
|
2017-09-07 |
2020-03-30 |
Revolution Medicines Inc |
Shp2 inhibitor compositions and methods for treating cancer
|
|
ES2985118T3
(es)
|
2017-09-08 |
2024-11-04 |
Amgen Inc |
Inhibidores de KRAS G12C y métodos de uso de los mismos
|
|
WO2019051469A1
(en)
|
2017-09-11 |
2019-03-14 |
Krouzon Pharmaceuticals, Inc. |
Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
|
|
CA3082579A1
(en)
|
2017-11-15 |
2019-05-23 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
TW201938561A
(zh)
|
2017-12-08 |
2019-10-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
|
MX2020011564A
(es)
|
2018-05-01 |
2021-01-29 |
Revolution Medicines Inc |
Analogos de rapamicina unidos a c26 como inhibidores de mtor.
|
|
CN118978535A
(zh)
|
2018-05-01 |
2024-11-19 |
锐新医药公司 |
作为mTOR抑制剂的C40-、C28-及C-32连接的雷帕霉素类似物
|
|
CA3099118A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
EP3788038B1
(en)
|
2018-05-04 |
2023-10-11 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
WO2019217307A1
(en)
|
2018-05-07 |
2019-11-14 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
TW202012415A
(zh)
|
2018-05-08 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
|
MA52564A
(fr)
|
2018-05-10 |
2021-03-17 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
|
MX2020012731A
(es)
|
2018-06-01 |
2021-02-22 |
Amgen Inc |
Inhibidores de kras g12c y metodos para su uso.
|
|
EP4268898A3
(en)
|
2018-06-11 |
2024-01-17 |
Amgen Inc. |
Kras g12c inhibitors for treating cancer
|
|
EP3807276B1
(en)
|
2018-06-12 |
2025-12-10 |
Amgen Inc. |
Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
|
US12134620B2
(en)
|
2018-08-01 |
2024-11-05 |
Araxes Pharma Llc |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
|
WO2020035031A1
(en)
|
2018-08-16 |
2020-02-20 |
Genentech, Inc. |
Fused ring compounds
|
|
WO2020047192A1
(en)
|
2018-08-31 |
2020-03-05 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
US10684219B2
(en)
|
2018-10-30 |
2020-06-16 |
Chevron U.S.A. Inc. |
Method for determining hydrocarbon concentration in drilled solids using near infrared spectroscopy
|
|
JP7454572B2
(ja)
|
2018-11-19 |
2024-03-22 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法
|
|
EP3897644A4
(en)
*
|
2018-12-21 |
2022-09-07 |
Revolution Medicines, Inc. |
CONNECTIONS INVOLVING IN A COOPERATIVE BINDING AND USES THEREOF
|
|
CN118619971A
(zh)
|
2019-09-20 |
2024-09-10 |
上海济煜医药科技有限公司 |
稠合吡啶酮类化合物及其制备方法和应用
|
|
MX2022005053A
(es)
|
2019-10-28 |
2022-05-18 |
Merck Sharp & Dohme Llc |
Inhibidores de peque?as moleculas de mutante g12c de kras.
|
|
KR20220109408A
(ko)
|
2019-11-04 |
2022-08-04 |
레볼루션 메디슨즈, 인크. |
Ras 억제제
|
|
PH12022550988A1
(en)
|
2019-11-04 |
2023-10-09 |
Revolution Medicines Inc |
Ras inhibitors
|
|
CN114901366A
(zh)
|
2019-11-04 |
2022-08-12 |
锐新医药公司 |
Ras抑制剂
|
|
WO2021108683A1
(en)
|
2019-11-27 |
2021-06-03 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
EP4143189A1
(en)
|
2020-04-30 |
2023-03-08 |
Gilead Sciences, Inc. |
Macrocyclic inhibitors of peptidylarginine deiminases
|
|
BR112021023814A2
(pt)
|
2020-06-09 |
2022-12-20 |
Pardes Biosciences Inc |
Inibidores de proteases de cisteína e métodos de uso das mesmas
|
|
MX2022016355A
(es)
|
2020-06-18 |
2023-04-03 |
Revolution Medicines Inc |
Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.
|
|
CA3187757A1
(en)
|
2020-09-03 |
2022-03-24 |
Ethan AHLER |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
IL301298A
(en)
|
2020-09-15 |
2023-05-01 |
Revolution Medicines Inc |
Indole derivatives as RAS inhibitors in cancer therapy
|
|
EP4225383A4
(en)
|
2020-10-08 |
2024-12-11 |
Kumquat Biosciences Inc. |
MODULATORS OF CELLULAR PROLIFERATION AND THEIR USES
|
|
AU2021409515A1
(en)
|
2020-12-22 |
2023-07-06 |
Hanmi Pharmaceutical Co., Ltd. |
Novel quinazoline derivatives as SOS1 inhibitors and use thereof
|
|
WO2022137085A1
(en)
|
2020-12-22 |
2022-06-30 |
Novartis Ag |
Indole derivatives useful in treating conditions associated with cgas
|
|
EP4267586A1
(en)
|
2020-12-22 |
2023-11-01 |
Pfizer Inc. |
Solid forms of an eif4e inhibitor
|
|
TW202308632A
(zh)
|
2021-04-02 |
2023-03-01 |
美商綜合醫院股份有限公司 |
抑制ras的方法
|
|
KR20240017814A
(ko)
|
2021-05-05 |
2024-02-08 |
바이오젠 엠에이 인코포레이티드 |
브루톤 티로신 키나제의 분해를 표적으로 하는 화합물
|
|
MX2023013045A
(es)
|
2021-05-05 |
2024-01-19 |
Constellation Pharmaceuticals Inc |
Moduladores de exonucleasa i de tres reparaciones principales (trex1).
|
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
AR125782A1
(es)
|
2021-05-05 |
2023-08-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
AR125787A1
(es)
|
2021-05-05 |
2023-08-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CA3219533A1
(en)
|
2021-05-25 |
2022-12-01 |
Kyle Seamon |
Methods for inhibiting ras
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
AU2024251729A1
(en)
|
2023-04-14 |
2025-11-13 |
Revolution Medicines, Inc. |
Synthesis of ras inhibitors
|
|
TW202448897A
(zh)
|
2023-04-14 |
2024-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
|
|
TW202442640A
(zh)
|
2023-04-14 |
2024-11-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑之合成
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|